A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of MHAA4549A, a Monoclonal Antibody, Administered as Monotherapy for the Treatment of Acute Uncomplicated Seasonal Influenza A Infection in Otherwise Healthy Adults

Trial Profile

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of MHAA4549A, a Monoclonal Antibody, Administered as Monotherapy for the Treatment of Acute Uncomplicated Seasonal Influenza A Infection in Otherwise Healthy Adults

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Oct 2017

At a glance

  • Drugs MHAA 4549A (Primary)
  • Indications Influenza A virus infections
  • Focus Adverse reactions
  • Sponsors Genentech
  • Most Recent Events

    • 10 Oct 2017 Trial has been completed in Spain.
    • 01 Sep 2017 Planned End Date changed from 8 Jan 2018 to 20 Nov 2017.
    • 01 Sep 2017 Planned primary completion date changed from 8 Jan 2018 to 20 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top